Profile data is unavailable for this security.
About the company
SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.
- Revenue in JPY (TTM)304.35bn
- Net income in JPY26.85bn
- Incorporated1925
- Employees3.74k
- LocationSanten Pharmaceutical Co Ltd3-9-19, Shimo-Shinjo, Higashiyodogawa-kuOSAKA-SHI 530-8552JapanJPN
- Phone+81 676648621
- Fax+81 663593827
- Websitehttps://www.santen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Towa Pharmaceutical Co Ltd | 235.95bn | 16.92bn | 154.45bn | 4.59k | 8.72 | 0.9053 | 4.38 | 0.6546 | 343.72 | 343.72 | 4,793.82 | 3,311.49 | 0.5582 | 1.49 | 3.60 | 51,428,070.00 | 4.00 | 4.21 | 4.91 | 5.63 | 35.90 | 39.23 | 7.17 | 7.23 | 1.62 | -- | 0.5666 | 21.01 | 9.13 | 16.74 | 634.80 | 3.72 | 28.20 | 10.86 |
Kissei Pharmaceutical Co Ltd | 77.43bn | 12.00bn | 172.10bn | 1.78k | 13.00 | 0.7019 | 10.48 | 2.22 | 268.51 | 268.51 | 1,728.18 | 4,972.53 | 0.3204 | 1.55 | 2.90 | 43,524,450.00 | 5.00 | 3.61 | 5.38 | 3.90 | 49.90 | 49.47 | 15.59 | 12.69 | 4.93 | -- | 0.006 | 34.87 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
KAKEN PHARMACEUTICAL CO., LTD. | 72.15bn | 7.27bn | 180.82bn | 1.14k | 20.49 | 1.05 | 18.02 | 2.51 | 192.09 | 192.09 | 1,906.84 | 3,763.43 | 0.422 | 1.98 | 3.23 | 63,566,520.00 | 4.25 | 6.83 | 4.88 | 7.87 | 53.41 | 54.78 | 10.08 | 14.48 | 3.98 | -- | 0.0263 | 51.25 | -1.29 | -5.21 | 47.52 | -14.70 | 0.3639 | 0.00 |
Nippon Shinyaku Co., Ltd. | 150.37bn | 27.37bn | 236.82bn | 2.21k | 8.30 | 0.9996 | 7.26 | 1.57 | 406.30 | 406.30 | 2,232.62 | 3,372.50 | 0.5976 | 1.37 | 3.20 | 67,949,390.00 | 10.88 | 10.45 | 12.41 | 12.31 | 66.81 | 61.27 | 18.20 | 16.47 | 3.73 | -- | 0.0114 | 32.62 | 2.83 | 5.26 | 13.32 | 9.66 | 45.93 | 12.12 |
Sumitomo Pharma Co Ltd | 329.55bn | -260.17bn | 239.14bn | 4.98k | -- | 1.48 | -- | 0.7257 | -654.85 | -654.85 | 829.49 | 404.89 | 0.328 | 1.20 | 3.88 | 66,174,100.00 | -25.89 | -5.07 | -45.34 | -7.73 | 60.22 | 69.99 | -78.94 | -12.28 | 0.419 | -- | 0.7079 | -- | -43.38 | -7.29 | -322.71 | -- | 4.02 | -- |
Sawai Group Holdings Co Ltd | 178.04bn | 17.78bn | 270.13bn | 3.48k | 15.22 | 1.26 | 8.94 | 1.52 | 404.94 | 584.99 | 4,058.78 | 4,883.08 | 0.4671 | 1.17 | 2.83 | 51,130,670.00 | 3.48 | 0.7104 | 4.62 | 0.9705 | 31.14 | 35.08 | 7.44 | 1.47 | 1.58 | 43.19 | 0.2927 | 88.13 | 8.04 | -0.8249 | 46.82 | -2.33 | 18.15 | 0.00 |
Tsumura & Co | 157.50bn | 23.56bn | 304.81bn | 4.14k | 12.80 | 1.07 | 8.45 | 1.94 | 310.18 | 310.18 | 2,073.96 | 3,712.37 | 0.3703 | 0.7043 | 2.29 | 38,061,620.00 | 5.90 | 4.81 | 7.39 | 5.89 | 47.59 | 50.98 | 15.94 | 12.65 | 2.31 | -- | 0.2058 | 32.16 | 7.71 | 4.52 | 1.37 | 2.74 | 17.54 | 5.84 |
Hisamitsu Pharmaceutical Co Inc | 145.42bn | 14.71bn | 334.53bn | 2.76k | 20.38 | 1.09 | 16.19 | 2.30 | 192.71 | 192.71 | 1,905.69 | 3,607.43 | 0.4413 | 3.01 | 3.61 | 52,707,500.00 | 4.62 | 4.22 | 5.50 | 4.82 | 55.74 | 58.62 | 10.47 | 10.03 | 3.09 | -- | 0.0042 | 53.05 | 10.42 | -0.2385 | 18.97 | -6.17 | 28.90 | 0.5989 |
Santen Pharmaceutical Co Ltd | 304.35bn | 26.85bn | 639.18bn | 3.74k | 23.49 | 2.04 | 13.97 | 2.10 | 74.76 | 74.76 | 844.65 | 862.32 | 0.7155 | 2.68 | 3.25 | 81,289,260.00 | 6.32 | 3.31 | 7.84 | 4.10 | 58.85 | 59.73 | 8.84 | 5.21 | 2.03 | 5.27 | 0.1604 | 82.21 | 8.22 | 5.23 | 278.09 | -3.58 | 5.10 | 4.88 |
Rohto Pharmaceutical Co Ltd | 278.03bn | 30.33bn | 827.33bn | 7.26k | 26.43 | 3.10 | 20.92 | 2.98 | 132.56 | 132.56 | 1,215.22 | 1,129.95 | 0.7642 | 2.21 | 4.37 | 38,300,730.00 | 8.42 | 8.54 | 11.70 | 11.79 | 57.76 | 58.59 | 11.02 | 10.30 | 1.27 | -- | 0.1513 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
Ono Pharmaceutical Co Ltd | 500.33bn | 120.95bn | 981.18bn | 3.85k | 7.76 | 1.14 | 7.06 | 1.96 | 253.57 | 253.57 | 1,052.07 | 1,726.26 | 0.5117 | 2.44 | 3.65 | 129,855,200.00 | 12.38 | 11.95 | 15.14 | 13.73 | 74.69 | 74.11 | 24.20 | 23.89 | 1.32 | -- | 0.1661 | 32.25 | 12.41 | 11.73 | 13.53 | 19.95 | -6.79 | 12.20 |
Data as of Sep 20 2024. Currency figures normalised to Santen Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
Holder | Shares | % Held |
---|---|---|
Black Creek Investment Management, Inc.as of 31 Mar 2024 | 20.84m | 5.73% |
Nomura Asset Management Co., Ltd.as of 31 May 2024 | 19.14m | 5.26% |
Silchester International Investors LLPas of 19 Apr 2024 | 18.29m | 5.03% |
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 31 Aug 2023 | 11.34m | 3.12% |
The Vanguard Group, Inc.as of 04 Sep 2024 | 10.26m | 2.82% |
Norges Bank Investment Managementas of 31 Dec 2023 | 9.11m | 2.50% |
Nikko Asset Management Co., Ltd.as of 31 Aug 2023 | 8.20m | 2.25% |
Massachusetts Financial Services Co.as of 31 Aug 2024 | 5.16m | 1.42% |
Daiwa Asset Management Co. Ltd.as of 30 Aug 2024 | 4.93m | 1.36% |
BlackRock Fund Advisorsas of 05 Sep 2024 | 3.85m | 1.06% |
More ▼
Data from 30 Jun 2024 - 19 Sep 2024Source: FactSet Research Systems Inc.